Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025

This bill increases federal funding for sickle cell disease programs from $4.455 million annually (2019-2023) to $8.205 million annually (2025-2029). It revises existing law to expand the focus from "prevention and treatment of sickle cell disease" to specifically include "treatment of sickle cell disease and the prevention and treatment of complications." These changes directly affect patients with sickle cell disease and related blood disorders by prioritizing care for complications and increasing available resources. The bill amends Section 1106(b) of the Public Health Service Act to implement these funding and policy adjustments.